Patents by Inventor Lena Tagmose

Lena Tagmose has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170319564
    Abstract: The present invention is directed to compounds of formula (I) which are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of A? deposits is beneficial such as Alzheimer's disease.
    Type: Application
    Filed: November 9, 2015
    Publication date: November 9, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Karsten Juhl, Lena Tagmose, Mauro Marigo
  • Publication number: 20170313658
    Abstract: The present invention is directed to compounds according to Formula (I) which compounds are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for 5 which the reduction of A? deposits is beneficial such as Alzheimer's disease.
    Type: Application
    Filed: November 9, 2015
    Publication date: November 2, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Karsten JUHL, Lena TAGMOSE, Mauro MARIGO
  • Publication number: 20170066741
    Abstract: The present invention is directed to novel inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of A? deposits is beneficial such as Alzheimer's disease.
    Type: Application
    Filed: February 17, 2015
    Publication date: March 9, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Karsten Juhl, Mauro Marigo, Lena Tagmose, Thomas Jensen
  • Publication number: 20170044151
    Abstract: The present invention provides compounds of Formula I for the treatment of neurodegenerative or cognitive diseases. The method further provides for piperidine-2-one and piperidine-2-thione intermediates to compounds of formula I.
    Type: Application
    Filed: August 10, 2016
    Publication date: February 16, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Karsten Juhl, Lena Tagmose, Mauro Marigo
  • Publication number: 20170042895
    Abstract: The present invention is directed to the combined use of BACE1 inhibitor of Formula I and a compound useful in active or passive Tau immunotherapy, a compound useful in active or passive A? peptide immunotherapy, an NMDA receptor antagonists, an acetylcholine esterase inhibitor, an antiepileptic, an anti-inflammatory drug, a Tau aggregation inhibitor or an SSRI for the treatment of neurodegenerative or cognitive disorders.
    Type: Application
    Filed: August 8, 2016
    Publication date: February 16, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Karsten Juhl, Mauro Marigo, Lena Tagmose, Thomas Jensen
  • Patent number: 9353084
    Abstract: The present invention is directed to novel inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of A? deposits is beneficial such as Alzheimer's disease.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: May 31, 2016
    Assignee: H. Lundbeck A/S
    Inventors: Karsten Juhl, Mauro Marigo, Lena Tagmose, Thomas Jensen
  • Patent number: 9346797
    Abstract: The present invention is directed to novel inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of A? deposits is beneficial such as Alzheimer's disease.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: May 24, 2016
    Assignee: H. Lundbeck A/S
    Inventors: Karsten Juhl, Lena Tagmose, Mauro Marigo
  • Publication number: 20160130267
    Abstract: The present invention is directed to novel inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of A? deposits is beneficial such as Alzheimer's disease.
    Type: Application
    Filed: November 5, 2015
    Publication date: May 12, 2016
    Applicant: H. LUNDBECK A/S
    Inventors: Karsten Juhl, Lena Tagmose, Mauro Marigo
  • Publication number: 20150232449
    Abstract: The present invention is directed to novel inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of A? deposits is beneficial such as Alzheimer's disease.
    Type: Application
    Filed: February 19, 2015
    Publication date: August 20, 2015
    Applicant: H. LUNDBECK A/S
    Inventors: Karsten Juhl, Mauro Marigo, Lena Tagmose, Thomas Jensen